Paratek Pharmaceuticals Inc (PRTK) is Omega Fund Management LLC’s Largest Position

Omega Fund Management LLC continued to hold its stake in shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,600,410 shares of the specialty pharmaceutical company’s stock at the end of the first quarter. Paratek Pharmaceuticals comprises 32.5% of Omega Fund Management LLC’s investment portfolio, making the stock its largest position. Omega Fund Management LLC owned approximately 0.11% of Paratek Pharmaceuticals worth $50,058,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of PRTK. State Street Corp raised its stake in shares of Paratek Pharmaceuticals by 21.5% in the fourth quarter. State Street Corp now owns 238,092 shares of the specialty pharmaceutical company’s stock valued at $3,668,000 after buying an additional 42,117 shares in the last quarter. Essex Investment Management Co. LLC raised its stake in shares of Paratek Pharmaceuticals by 15.6% in the first quarter. Essex Investment Management Co. LLC now owns 51,426 shares of the specialty pharmaceutical company’s stock valued at $990,000 after buying an additional 6,939 shares in the last quarter. Norges Bank purchased a new stake in shares of Paratek Pharmaceuticals during the fourth quarter valued at about $1,486,000. Candriam Luxembourg S.C.A. purchased a new stake in shares of Paratek Pharmaceuticals during the first quarter valued at about $2,310,000. Finally, Rock Springs Capital Management LP raised its stake in shares of Paratek Pharmaceuticals by 20.1% in the third quarter. Rock Springs Capital Management LP now owns 502,500 shares of the specialty pharmaceutical company’s stock valued at $6,538,000 after buying an additional 84,000 shares in the last quarter. 76.06% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) traded up 0.70% during mid-day trading on Friday, hitting $21.55. The stock had a trading volume of 674,181 shares. The stock’s market cap is $592.30 million. The stock’s 50-day moving average price is $21.95 and its 200-day moving average price is $16.52. Paratek Pharmaceuticals Inc has a 12 month low of $9.80 and a 12 month high of $25.00.

Paratek Pharmaceuticals (NASDAQ:PRTK) last released its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($1.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.20) by $0.06. The company had revenue of $0.02 million for the quarter.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Mideast Time and is the property of of Mideast Time. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.mideasttime.com/paratek-pharmaceuticals-inc-prtk-is-omega-fund-management-llcs-largest-position/1709212.html.

Several analysts have issued reports on PRTK shares. Zacks Investment Research raised Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research note on Thursday, April 20th. HC Wainwright increased their price objective on Paratek Pharmaceuticals from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, April 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $32.00 price objective on shares of Paratek Pharmaceuticals in a research note on Thursday, March 30th. Guggenheim reissued a “buy” rating on shares of Paratek Pharmaceuticals in a research note on Monday, March 27th. Finally, Robert W. Baird reissued a “positive” rating and set a $40.00 price objective on shares of Paratek Pharmaceuticals in a research note on Monday, March 27th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $36.80.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

12 Month Chart for NASDAQ:PRTK

Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals Inc (NASDAQ:PRTK).

Receive News & Ratings for Paratek Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.